Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen, J S Johansen, Christian Dehlendorff, J S Larsen, K Osterlind, J Hansen, S E Nielsen, P Pfeiffer, Line Schmidt Tarpgaard, N H Holländer, N Keldsen, T F Hansen, B B Jensen, B V Jensen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.
Original languageEnglish
JournalAnnals of Oncology
Volume24
Issue number10
Pages (from-to)2554-2559
ISSN0923-7534
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Bevacizumab
  • Biomarker
  • Chemotherapy
  • Metastatic colorectal cancer
  • Primary tumor

Fingerprint Dive into the research topics of 'Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Osterlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., Keldsen, N., Hansen, T. F., Jensen, B. B., & Jensen, B. V. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology, 24(10), 2554-2559. https://doi.org/10.1093/annonc/mdt253